Needham analyst Ami Fadia maintained a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) today and set a price target of $202.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ami Fadia has given his Buy rating due to a combination of factors surrounding Jazz Pharmaceuticals’ potential for growth. The expansion of Zepzelca into the first-line maintenance setting is expected to significantly increase its market reach by tapping into a broader patient base and extending the duration of therapy. This strategic move is anticipated to drive substantial revenue growth, even as competition emerges.
Despite potential competitive pressures from treatments like Imdeltra and Durva, these are expected to be limited to academic settings due to their adverse event profiles. Consequently, Jazz Pharmaceuticals is projected to achieve over $800 million in U.S. sales by 2029. The inclusion of Zepzelca in the NCCN guidelines and anticipated FDA approval further bolster its growth prospects, justifying the Buy rating.
In another report released on June 3, TD Cowen also maintained a Buy rating on the stock with a $205.00 price target.